A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
Status:
Not yet recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and patient reported outcomes of chidamide 20
mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given
on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central
nervous system lymphoma.
The primary study endpoint will be complete response (CR) rate as assessed by the
investigator. The hypothesis is previously untreated patients with primary central nervous
system lymphoma could achieve a CR rate of 80% with C-R-HDMTX.